A novel TRIM22 gene polymorphism promotes the response to PegIFNα therapy through cytokine-cytokine receptor interaction signaling pathway in chronic hepatitis B

Pegylated interferon alfa (PegIFNα) has limited efficacy in the treatment of chronic hepatitis B (CHB). Although many biomarkers related to hepatitis B virus (HBV) have been proposed to stratify patients, the response rate to PegIFNα is still unsatisfactory. Herein, our data suggest that the single-...

Full description

Saved in:

Bibliographic Details
Published in:	Microbiology spectrum Vol. 11; no. 6; p. e0224723
Main Authors:	Wang, Long, Lin, Ni, Zhang, Yanfang, Guo, Shaoying, Liu, Can, Lin, Caorui, Zeng, Yongbin, Wu, Wennan, Guo, Jianhui, Zhu, Chenggong, Zhan, Fuguo, Ou, Qishui, Xun, Zhen
Format:	Journal Article
Language:	English
Published:	United States American Society for Microbiology 12-12-2023
Subjects:	Antiviral Agents - therapeutic use chronic hepatitis B Clinical Microbiology DNA, Viral Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - genetics Humans Interferon-alpha - genetics Interferon-alpha - pharmacology Minor Histocompatibility Antigens - genetics Minor Histocompatibility Antigens - therapeutic use pegylated interferon alfa Polymorphism, Single Nucleotide Receptors, Cytokine - genetics Receptors, Cytokine - therapeutic use Recombinant Proteins - genetics Recombinant Proteins - therapeutic use Repressor Proteins - genetics Research Article Signal Transduction single-nucleotide polymorphism Treatment Outcome Tripartite Motif Proteins - genetics Tripartite Motif Proteins - metabolism tripartite motif-containing 22 chronic hepatitis B tripartite motif-containing 22 pegylated interferon alfa single-nucleotide polymorphism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Pegylated interferon alfa (PegIFNα) has limited efficacy in the treatment of chronic hepatitis B (CHB). Although many biomarkers related to hepatitis B virus (HBV) have been proposed to stratify patients, the response rate to PegIFNα is still unsatisfactory. Herein, our data suggest that the single-nucleotide polymorphism (SNP) rs10838543 in TRIM22 potentiates a positive clinical response to PegIFNα treatment in patients with hepatitis B e antigen-positive CHB by increasing the levels of IFNL1, CCL3, and CCL5. These observations can help guide treatment decisions for patients with CHB to improve the response rate to PegIFNα.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Long Wang, Ni Lin, and Yanfang Zhang contributed equally to this article. Author order was determined by drawing straws. The authors declare no conflict of interest.
ISSN:	2165-0497 2165-0497
DOI:	10.1128/spectrum.02247-23